Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online. “These presentations reflect Acumen's commitment to understanding the biology of early AD as well as the full experience, including the perspectives of patients and care partners living with it every day,” said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. “These important insights from our study collaborators and participants in ALTITUDE-AD help keep their needs at the center of our efforts to advance sabirnetug as a potential treatment of choice for AD.”

GlobeNewsWire • 12 hours ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

GlobeNewsWire • Oct 19, 2026

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Zacks Investment Research • Sep 21, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Seeking Alpha • Sep 16, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 10, 2026

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

GlobeNewsWire • Sep 10, 2026

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.

GlobeNewsWire • Sep 2, 2026

Acumen Pharmaceuticals Q2 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.

MarketBeat • Aug 12, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.

GlobeNewsWire • Aug 12, 2026